[go: up one dir, main page]

WO2024254161A3 - Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making - Google Patents

Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making Download PDF

Info

Publication number
WO2024254161A3
WO2024254161A3 PCT/US2024/032570 US2024032570W WO2024254161A3 WO 2024254161 A3 WO2024254161 A3 WO 2024254161A3 US 2024032570 W US2024032570 W US 2024032570W WO 2024254161 A3 WO2024254161 A3 WO 2024254161A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
fabps
disclosed
inhibitors
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/032570
Other languages
French (fr)
Other versions
WO2024254161A2 (en
Inventor
Liraz LEVI
Tej PAREEK
Elizabeth MEYERS
Seunghwan LIM
William J. Greenlee
Seong-Jin Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celloram Inc
Original Assignee
Celloram Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celloram Inc filed Critical Celloram Inc
Publication of WO2024254161A2 publication Critical patent/WO2024254161A2/en
Publication of WO2024254161A3 publication Critical patent/WO2024254161A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases including cancers that highly express any of these FABPs, in particular triple-negative breast cancer (TNBC) and other inflammation-induced diseases including cardiovascular disease, obesity or an obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting glucose, vitiligo, psoriasis, autoimmune disorders, pain and dementia. Also disclosed herein are methods for preparing the disclosed compounds.
PCT/US2024/032570 2023-06-05 2024-06-05 Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making Pending WO2024254161A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363471207P 2023-06-05 2023-06-05
US63/471,207 2023-06-05

Publications (2)

Publication Number Publication Date
WO2024254161A2 WO2024254161A2 (en) 2024-12-12
WO2024254161A3 true WO2024254161A3 (en) 2025-04-17

Family

ID=93794699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/032570 Pending WO2024254161A2 (en) 2023-06-05 2024-06-05 Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making

Country Status (1)

Country Link
WO (1) WO2024254161A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025226670A1 (en) * 2024-04-23 2025-10-30 Celloram, Inc. Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164103A1 (en) * 2005-05-13 2012-06-28 Vertex Pharmaceuticals (Canada) Incorporated Compounds and Methods for the Treatment or Prevention of Flavivirus Infections
WO2014040938A1 (en) * 2012-09-12 2014-03-20 F. Hoffmann-La Roche Ag Non-annulated thiophenylamides as inhibitors of fatty acid binding proteini(fabp) 4 and/or 5
US20150175594A1 (en) * 2012-06-19 2015-06-25 Hoffmann-La Roche Inc. New bicyclic thiophenylamide compounds
WO2019243550A1 (en) * 2018-06-21 2019-12-26 UCB Biopharma SRL Thiophene derivatives for the treatment of disorders caused by ige
US20230150931A1 (en) * 2021-09-15 2023-05-18 Novius Therapeutics, Llc Fabp4/5 inhibitors, methods of use and methods of making

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164103A1 (en) * 2005-05-13 2012-06-28 Vertex Pharmaceuticals (Canada) Incorporated Compounds and Methods for the Treatment or Prevention of Flavivirus Infections
US20150175594A1 (en) * 2012-06-19 2015-06-25 Hoffmann-La Roche Inc. New bicyclic thiophenylamide compounds
US9604977B2 (en) * 2012-06-19 2017-03-28 Hoffman-La Roche Inc. Bicyclic thiophenylamide compounds
WO2014040938A1 (en) * 2012-09-12 2014-03-20 F. Hoffmann-La Roche Ag Non-annulated thiophenylamides as inhibitors of fatty acid binding proteini(fabp) 4 and/or 5
WO2019243550A1 (en) * 2018-06-21 2019-12-26 UCB Biopharma SRL Thiophene derivatives for the treatment of disorders caused by ige
US20230150931A1 (en) * 2021-09-15 2023-05-18 Novius Therapeutics, Llc Fabp4/5 inhibitors, methods of use and methods of making

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Compound 29 January 2016 (2016-01-29), PUBCHEM PUBCHEM: "2-sulfanyl-N-thiophen-2-ylacetamide | C6H7NOS2 | CID 115166896 - PubChem", XP093305535, Database accession no. 115166896 *

Also Published As

Publication number Publication date
WO2024254161A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
Ahmad et al. Brown/Beige adipose tissues and the emerging role of their secretory factors in improving metabolic health: The batokines
WO2003068746A8 (en) Aryl ureas as kinase inhibitors
Cooper et al. Rapid reversed phase ultra-performance liquid chromatography analysis of the major cocoa polyphenols and inter-relationships of their concentrations in chocolate
Sanjeewa et al. Anti-inflammatory activity of a sulfated polysaccharide isolated from an enzymatic digest of brown seaweed Sargassum horneri in RAW 264.7 cells
Bitzer et al. Cocoa procyanidins with different degrees of polymerization possess distinct activities in models of colonic inflammation
WO2024254161A3 (en) Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making
Ahsan et al. Synthesis, antiproliferative activity, and molecular docking studies of curcumin analogues bearing pyrazole ring
WO2003024395A3 (en) Linked biaryl compounds
EP1304110A3 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
TW200602070A (en) Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
WO2005051366A3 (en) Diaryl urea derivatives in the treatment of protein kinase dependent diseases
WO2006044860A3 (en) Thiadiazole compounds and methods of use
WO2006081230A3 (en) 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
AU2002363175A1 (en) Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
WO2002078617A3 (en) Materials and methods for treatment of cancer and identification of anti-cancer compounds
WO2001001748A3 (en) Peptide compounds that bind her2
EE200200123A (en) A tyrosine kinase inhibiting compound, a pharmaceutical composition comprising it, and a therapeutic use
WO2004099192A3 (en) Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EP0397060A3 (en) Maleinimide derivatives and their use as medicines
EP1284734A4 (en) Protein kinase inhibitors
WO2004099168A3 (en) Substituted carboxylic acids
WO2004099171A3 (en) Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
TW200630327A (en) Substituted phenylalkanoic acids
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
Alu’datt et al. Investigation of natural lipid–phenolic interactions on biological properties of virgin olive oil

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024284676

Country of ref document: AU